- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05223608 | Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy(ImmuCCo) | recruiting | N/A | 651 | Centre Oscar LambretOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT00900471 | Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors | recruiting | — | 20,000 | Wake Forest University Health SciencesOTHER | 1 | Mar 19, 2026 |
| clinicaltrials |
| NCT00571389 | A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells. | recruiting | — | 1,500 | BioCytics, Inc.INDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04443088 | An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors(KEYNOTE-E12) | recruiting | Phase 1 | 78 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05689853 | Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 87 | AkesoINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07417189 | A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) | recruiting | Phase 1 / Phase 2 | 401 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04932525 | Gustave Roussy Cancer Profiling(STING) | recruiting | N/A | 20,000 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03465592 | Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | recruiting | Phase 1 / Phase 2 | 39 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06397963 | Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours | recruiting | N/A | 18 | Grit BiotechnologyINDUSTRY | 1 | Jan 26, 2026 | clinicaltrials |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | recruiting | Phase 1 / Phase 2 | 348 | Corbus Pharmaceuticals Inc.INDUSTRY | 7 | Jan 8, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT02215928 | Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors | recruiting | — | 100 | Stanford UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT06383884 | Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion | recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06439888 | Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer(LySATRA) | recruiting | Phase 1 / Phase 2 | 58 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06504368 | Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors | recruiting | Phase 1 | 32 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04643418 | Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 81 | MegaPro Biomedical Co. Ltd.INDUSTRY | 1 | Nov 3, 2025 | clinicaltrials |
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs(KYANITE-1) | recruiting | Phase 1 / Phase 2 | 250 | Krystal Biotech, Inc.INDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT04954599 | Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | recruiting | Phase 1 / Phase 2 | 126 | Maastricht University Medical CenterOTHER | 3 | Oct 7, 2025 | clinicaltrials |
| NCT05055609 | Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors | recruiting | Phase 1 | 94 | TretheraINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT03772561 | Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies(MEDIPAC) | recruiting | Phase 1 | 40 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05481502 | An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors(PIONEER) | recruiting | N/A | 160 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06911333 | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors(AD1208) | recruiting | Phase 1 / Phase 2 | 36 | Avelos Therapeutics Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06895733 | Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | recruiting | Phase 1 / Phase 2 | 65 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06897228 | PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors | recruiting | Phase 1 | 18 | Shenzhen Celconta Life Science Co., Ltd.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06883539 | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. | recruiting | Phase 1 | 24 | LaunXP Biomedical Co., Ltd.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04196257 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | recruiting | Phase 1 | 50 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06350539 | Personalized Models for Cancer Research | recruiting | — | 500 | New York Stem Cell Foundation Research InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06032845 | Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)(CASTLE-11) | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06436157 | A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention(GENESIS) | recruiting | N/A | 60 | University of California, DavisOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06003621 | Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients(MoST-TAP) | recruiting | Phase 2 | 96 | OmicoOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06622486 | First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 50 | Egle TherapeuticsINDUSTRY | 2 | Nov 7, 2024 | clinicaltrials |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06477614 | Anti-cancer DC Cell Vaccination to Treat Solid Tumors | recruiting | Phase 1 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06478108 | Interventional Software for Multi-immunotherapy of Solid Tumors | recruiting | Phase 2 / Phase 3 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06195293 | Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06195384 | Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03778814 | TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04803318 | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | recruiting | Phase 1 | 40 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05779917 | Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06404528 | Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours | recruiting | N/A | 300 | Wuxi People's HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | recruiting | Phase 1 | 36 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 30, 2026source: clinicaltrials